"New Obesity and Diabetes Drug Could Revolutionize Weight Loss Market"
TL;DR Summary
Eli Lilly is seeking FDA approval for a new obesity drug that could disrupt the weight loss market. The drug, tirzepatide, has shown promising results in clinical trials, with patients losing an average of 14.9% of their body weight. If approved, tirzepatide could compete with other weight loss drugs on the market and potentially become a blockbuster drug for Eli Lilly.
- Eli Lilly to seek obesity drug approval that could disrupt weight loss market Financial Times
- Powerful new obesity drug poised to upend weight loss care Yahoo News
- Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 pounds CNBC
- Diabetes drug tested for weight loss could be game changer Fox Business
- Popular diabetes drug Mounjaro shows weight loss results in new study GMA
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
48%
117 → 61 words
Want the full story? Read the original article
Read on Financial Times